Dudnyk blog
5 things biotech brand managers should know about their data
Experts often possess more data than judgment.
– Colin Powell
Your promotional materials are supported by data from clinical trials. Piles of numbers can intimidate even the brightest and most intrepid brand manager, so here are 5 ways to cut through the clutter and separate the wheat from the chaff.
1. Know the “trust hierarchy” of data
It’s important to know that not all data sources are created equal in the eyes of the scientific and medical community. The clinical study report (CSR) is Holy Grail of resources. It is the original and complete data source for a study, and has the most correct version of your data available.
A manuscript published in a peer-reviewed journal is the second most reliable source. Non-peer-reviewed publications and posters presented at congresses share the bronze medal in data reliability.
2. Have a close relationship with your peers in medical affairs or scientific communications
As a brand manager, you are not tasked with being your data’s keeper. If one day you quickly need to obtain a study protocol, CSR, or publication, know whom to ask.
Managers in your company’s medical affairs or scientific communications departments handle the numbers on a daily basis. Get to know them.
3. Statistical vs. clinical significance
Suppose a test on some of your data concludes that P<0.05, making the result statistically significant. Does this mean the result is important? Perhaps not.
A physician may see a small effect size and decide that the difference is simply insufficient to be relevant or influence clinical practice, no matter the P value. Don’t just follow the statistics, do your homework to learn what your audience will believe.
4. Know what study endpoints mean to physicians
Your studies likely have several primary and secondary endpoints. Some may be germane to the way your target physician practices medicine, while others may simply indicate to a reviewer or the NIH that you’ve covered all your bases.
Does a physician care more about the way your drug influences a particular biomarker of the disease, or about the way your drug could improve a patient’s quality of life?
Both measures can be endpoints in your study, but your brand’s performance will reflect your understanding of which has greater clinical and/or emotional appeal. Conduct your research accordingly.
5. Ensure consistency and eliminate errors
It may seem a no-brainer, yet we are often surprised by mistakes and inconsistencies in the data provided to us by clients. To minimize embarrassing interactions with your med-legal review team and wasted time with your agency partners (worse yet, the possibility of errors creeping into promotional materials), start by putting the first suggestion on this list (knowing the trust hierarchy of data) into practice.
Use the most reliable data source available, preferably the CSR, and check everything against it. The fewer derivative materials comprise the supporting evidence for your brand, the more consistent and accurate the promotion will become.
Serve your brand and ensure accuracy by knowing where your data come from, what it means, and to whom.











Years ago when I first participated as an editor during copy review meetings I was struck by the contentiousness I’d observe around the room, as if marketing and MLR teams had an innate distrust of each other. This post spells out for marketers the importance of being prepared before a meeting–and of treating MLR as an advocate instead of as an adversary.
I didn’t have any kind of primer on consideration of sourcing and other nuances of scientific data when I started working in the pharmaceutical industry several years ago. I wish I had something like this to shed light on the issues that can make or break copy approval!
I’m sure newbies reading this will find the details and advice helpful for filling in knowledge gaps.